Co-Diagnostics (CODX) Stock Analysis & Winston Score

Co-Diagnostics is a small biotechnology company that makes diagnostic tests used to detect diseases and infections. Its main products are molecular diagnostic tests — tools that identify specific genetic material from pathogens like viruses or bacteria. The company became widely known during the COVID-19 pandemic for selling PCR-based coronavirus tests to hospitals, labs, and public health agencies. The company earns revenue by selling test kits and related reagents, primarily to healthcare providers and government health programs. It operates mainly in the United States but has sold products internationally, including in developing markets. Co-Diagnostics built its tests around a proprietary DNA chemistry platform called CoPrimer, which it claims improves accuracy and reduces costs compared to standard methods. However, COVID-19 test demand has collapsed since its peak, and the company is now burning through cash while trying to expand into new disease targets — making its ability to find sustainable revenue beyond pandemic testing the central challenge it faces.